As Sanofi prunes pipeline, ex-Alexion crew at Rallybio picks up anemia drug

Sanofi has out-licensed its KY1066 antibody to New Haven, CT-based Rallybio who has redubbed it RLYB331. The deal saw Rallybio make an upfront cash payment of $3 million to Sanofi in addition to promising development and commercial milestones and mid to high single-digit royalties on net sales.

Continue ReadingAs Sanofi prunes pipeline, ex-Alexion crew at Rallybio picks up anemia drug

Abbvie and Plexium Enter into Multi-target Strategic Collaboration to Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions

San Diego, California, [April 28, 2022] – Plexium, Inc. (Plexium) and AbbVie (NYSE: ABBV) have entered into an exclusive strategic collaboration to develop

Continue ReadingAbbvie and Plexium Enter into Multi-target Strategic Collaboration to Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions

Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency

Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced positive preliminary biomarker, safety, and pharmacokinetic (PK) data…

Continue ReadingInozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency